MA53541A - Dérivés hétéroaryles bicycliques - Google Patents
Dérivés hétéroaryles bicycliquesInfo
- Publication number
- MA53541A MA53541A MA053541A MA53541A MA53541A MA 53541 A MA53541 A MA 53541A MA 053541 A MA053541 A MA 053541A MA 53541 A MA53541 A MA 53541A MA 53541 A MA53541 A MA 53541A
- Authority
- MA
- Morocco
- Prior art keywords
- bicyclic derivatives
- heteroaryl bicyclic
- heteroaryl
- derivatives
- bicyclic
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/553—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one oxygen as ring hetero atoms, e.g. loxapine, staurosporine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP18192219 | 2018-09-03 | ||
| PCT/EP2019/073303 WO2020048904A1 (fr) | 2018-09-03 | 2019-09-02 | Dérivés hétéroaryles bicycliques |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA53541A true MA53541A (fr) | 2021-12-08 |
| MA53541B1 MA53541B1 (fr) | 2024-02-29 |
Family
ID=63490310
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA53541A MA53541B1 (fr) | 2018-09-03 | 2019-09-02 | Dérivés hétéroaryles bicycliques |
Country Status (31)
| Country | Link |
|---|---|
| US (1) | US12084461B2 (fr) |
| EP (1) | EP3846903B1 (fr) |
| JP (1) | JP7398435B2 (fr) |
| KR (1) | KR20210054515A (fr) |
| CN (1) | CN112566696B (fr) |
| AR (1) | AR116051A1 (fr) |
| AU (1) | AU2019336492B2 (fr) |
| BR (1) | BR112021002170A2 (fr) |
| CA (1) | CA3107593A1 (fr) |
| CL (1) | CL2021000486A1 (fr) |
| CO (1) | CO2021002415A2 (fr) |
| CR (1) | CR20210104A (fr) |
| DK (1) | DK3846903T3 (fr) |
| ES (1) | ES2966947T3 (fr) |
| FI (1) | FI3846903T3 (fr) |
| HR (1) | HRP20231663T1 (fr) |
| HU (1) | HUE064554T2 (fr) |
| IL (1) | IL281175B2 (fr) |
| LT (1) | LT3846903T (fr) |
| MA (1) | MA53541B1 (fr) |
| MX (1) | MX2021002087A (fr) |
| PE (1) | PE20210860A1 (fr) |
| PH (1) | PH12021550320A1 (fr) |
| PL (1) | PL3846903T3 (fr) |
| PT (1) | PT3846903T (fr) |
| RS (1) | RS64950B1 (fr) |
| SG (1) | SG11202102137SA (fr) |
| SI (1) | SI3846903T1 (fr) |
| TW (1) | TWI841592B (fr) |
| UA (1) | UA128482C2 (fr) |
| WO (1) | WO2020048904A1 (fr) |
Family Cites Families (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5994349A (en) | 1997-10-27 | 1999-11-30 | Howard University | 3-carboalkoxy-2, 3-dihydro-1H-phenothiazin-4[10H]-one derivatives |
| NZ507169A (en) | 1998-04-01 | 2004-02-27 | Cardiome Pharma Corp | Aminocyclohexyl ether compounds and uses thereof |
| AU2528900A (en) | 1999-02-12 | 2000-08-29 | Nortran Pharmaceuticals Inc. | Cycloalkyl amine compounds and uses thereof |
| US7507545B2 (en) | 1999-03-31 | 2009-03-24 | Cardiome Pharma Corp. | Ion channel modulating activity method |
| AU5289600A (en) | 1999-05-25 | 2000-12-12 | Neurogen Corporation | 4h-1,4-benzothiazine-2-carboxamides and their use as gaba brain receptor ligands |
| EP1218003A4 (fr) | 1999-09-13 | 2004-02-11 | David M Swope | Composition et procede pour la reduction de la symptomatologie neurologique |
| US7057053B2 (en) | 2000-10-06 | 2006-06-06 | Cardiome Pharma Corp. | Ion channel modulating compounds and uses thereof |
| US8703753B2 (en) | 2005-09-15 | 2014-04-22 | Biomas Ltd. | Use of tellurium compounds for the treatment of actinic keratosis |
| MX2009012163A (es) | 2007-05-11 | 2009-12-01 | Hoffmann La Roche | Hetarilanilinas como moduladores para beta-amiloide. |
| KR101569391B1 (ko) | 2007-10-19 | 2015-11-16 | 얀센 파마슈티카 엔.브이. | γ-세크레타아제의 피페리디닐 및 피페라지닐 조절제 |
| WO2010056849A1 (fr) | 2008-11-13 | 2010-05-20 | Schering Corporation | Modulateurs de gamma sécrétase |
| PE20120172A1 (es) | 2009-02-26 | 2012-03-08 | Eisai Randd Man Co Ltd | Compuestos heterociclicos fusionados que contiene nitrogeno como inhibidores de la produccion de beta-amiloide |
| WO2010138901A1 (fr) | 2009-05-29 | 2010-12-02 | Biogen Idec Ma Inc | Composés contenant de l'acide carboxylique, leurs dérivés et procédés d'utilisation associés |
| CA2767764A1 (fr) * | 2009-07-13 | 2011-01-20 | Takeda Pharmaceutical Company Limited | Compose heterocyclique et son utilisation |
| EP2443657A4 (fr) | 2009-09-04 | 2013-07-31 | Hewlett Packard Development Co | Memristances basées sur des composés métalliques à valence mixte |
| US20110190269A1 (en) | 2010-02-01 | 2011-08-04 | Karlheinz Baumann | Gamma secretase modulators |
| US8486967B2 (en) | 2010-02-17 | 2013-07-16 | Hoffmann-La Roche Inc. | Heteroaryl substituted piperidines |
| US8703763B2 (en) | 2011-03-02 | 2014-04-22 | Hoffmann-La Roche Inc. | Bridged piperidine derivatives |
| EP2731948B1 (fr) * | 2011-07-15 | 2015-09-09 | Janssen Pharmaceuticals, Inc. | Nouveaux dérivés d'indole substitués utilisés en tant que modulateurs de la gamma-sécrétase |
| WO2014060112A1 (fr) | 2012-10-19 | 2014-04-24 | Origenis Gmbh | Pyrazolo[4,3-d]pyrimidines utiles en tant qu'inhibiteurs de kinases |
| CN107922437B (zh) | 2015-09-09 | 2021-12-10 | 豪夫迈·罗氏有限公司 | 桥连哌啶衍生物 |
| WO2017097728A1 (fr) | 2015-12-10 | 2017-06-15 | F. Hoffmann-La Roche Ag | Dérivés de pipéridine pontés |
| WO2018001918A1 (fr) | 2016-06-27 | 2018-01-04 | F. Hoffmann-La Roche Ag | Triazolopyridines en tant que modulateurs de gamma-sécrétase |
| AR109829A1 (es) * | 2016-09-29 | 2019-01-30 | Hoffmann La Roche | Derivados de piperidina puenteados |
| WO2018083050A1 (fr) * | 2016-11-01 | 2018-05-11 | F. Hoffmann-La Roche Ag | Dérivés hétéroaryle bicycliques |
| EP3538516B1 (fr) | 2016-11-08 | 2021-06-16 | F. Hoffmann-La Roche AG | Phénoxytriazoles |
| JP6904612B2 (ja) | 2016-12-16 | 2021-07-21 | パイプライン セラピューティクス， インコーポレイテッド | 蝸牛シナプス障害を処置する方法 |
| US11370802B2 (en) | 2018-01-22 | 2022-06-28 | Hoffmann-La Roche, Inc. | Triazolo-azepine derivatives |
-
2019
- 2019-09-02 PL PL19759411.2T patent/PL3846903T3/pl unknown
- 2019-09-02 MA MA53541A patent/MA53541B1/fr unknown
- 2019-09-02 PT PT197594112T patent/PT3846903T/pt unknown
- 2019-09-02 IL IL281175A patent/IL281175B2/en unknown
- 2019-09-02 BR BR112021002170-1A patent/BR112021002170A2/pt unknown
- 2019-09-02 KR KR1020217006240A patent/KR20210054515A/ko active Pending
- 2019-09-02 SI SI201930682T patent/SI3846903T1/sl unknown
- 2019-09-02 PE PE2021000165A patent/PE20210860A1/es unknown
- 2019-09-02 JP JP2021512272A patent/JP7398435B2/ja active Active
- 2019-09-02 RS RS20231189A patent/RS64950B1/sr unknown
- 2019-09-02 CA CA3107593A patent/CA3107593A1/fr active Pending
- 2019-09-02 FI FIEP19759411.2T patent/FI3846903T3/fi active
- 2019-09-02 ES ES19759411T patent/ES2966947T3/es active Active
- 2019-09-02 CN CN201980054254.2A patent/CN112566696B/zh active Active
- 2019-09-02 CR CR20210104A patent/CR20210104A/es unknown
- 2019-09-02 AU AU2019336492A patent/AU2019336492B2/en active Active
- 2019-09-02 LT LTEPPCT/EP2019/073303T patent/LT3846903T/lt unknown
- 2019-09-02 US US17/273,278 patent/US12084461B2/en active Active
- 2019-09-02 EP EP19759411.2A patent/EP3846903B1/fr active Active
- 2019-09-02 WO PCT/EP2019/073303 patent/WO2020048904A1/fr active Application Filing
- 2019-09-02 TW TW108131458A patent/TWI841592B/zh active
- 2019-09-02 MX MX2021002087A patent/MX2021002087A/es unknown
- 2019-09-02 AR ARP190102494A patent/AR116051A1/es unknown
- 2019-09-02 DK DK19759411.2T patent/DK3846903T3/da active
- 2019-09-02 HR HRP20231663TT patent/HRP20231663T1/hr unknown
- 2019-09-02 HU HUE19759411A patent/HUE064554T2/hu unknown
- 2019-09-02 SG SG11202102137SA patent/SG11202102137SA/en unknown
- 2019-09-02 UA UAA202101190A patent/UA128482C2/uk unknown
-
2021
- 2021-02-15 PH PH12021550320A patent/PH12021550320A1/en unknown
- 2021-02-24 CO CONC2021/0002415A patent/CO2021002415A2/es unknown
- 2021-02-26 CL CL2021000486A patent/CL2021000486A1/es unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| PT3958977T (pt) | Derivados de camptotecina | |
| DK3956033T3 (da) | Bicykliske forbindelser | |
| DK3728252T3 (da) | 4-azaindolforbindelser | |
| DK3687999T3 (da) | Rapamycinderivater | |
| LT3810602T (lt) | Junginiai | |
| EP3897842C0 (fr) | Dérivés bicycliques | |
| EP3280707C0 (fr) | Dérivés de quinazolinone bicyclique | |
| EP3810129A4 (fr) | Composés bicycliques antagonistes de pcsk9 | |
| LT3830085T (lt) | Deuterinti lanifibranoro dariniai | |
| DK3768669T3 (da) | Piperazinazaspiroderivater | |
| DK3898637T3 (da) | Rapamycin-derivater | |
| EP3884940A4 (fr) | Nouveau dérivé d'imidazole | |
| EP3617195A4 (fr) | Nouveaux dérivés de tétrahydronaphtyle urée | |
| DK3823970T3 (da) | Yderligere substituerede triazoloquinoxalinderivater | |
| DK3823971T3 (da) | Substituerede triazol-quinoxalin-derivater | |
| EP4013751C0 (fr) | Dérivés de 2-hydroxycycloalcane-1-carbamoyle | |
| PT3796975T (pt) | Derivados de sulfonilaminobenzamida | |
| RS65128B1 (sr) | Jedinjenja | |
| DK3894410T3 (da) | Substituerede xanthinderivater | |
| EP4021904C0 (fr) | Dérivés d'alpha-d-galactopyranoside | |
| EP3413892A4 (fr) | Dérivés de tétrahydroisoquinoline | |
| MA56504A (fr) | Dérivés de pyridin-3-yle | |
| MA41641A (fr) | Dérivés de tétrahydropyranylbenzamide | |
| MA51126A (fr) | Dérivés de 2-oxo-1-pyrrolidinyl imidazothiadiazole | |
| EP3914359A4 (fr) | Dérivés de salicylamine liés au triphénylphosphonium |